用于高通量筛选的1型人类免疫缺陷病毒潜伏模型。
Human immunodeficiency virus type 1 latency model for high-throughput screening.
作者信息
Micheva-Viteva Sofiya, Pacchia Annmarie L, Ron Yacov, Peltz Stuart W, Dougherty Joseph P
机构信息
Department of Molecular Genetics, Microbiology and Immunology, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, New Jersey 08854, USA.
出版信息
Antimicrob Agents Chemother. 2005 Dec;49(12):5185-8. doi: 10.1128/AAC.49.12.5185-5188.2005.
Abstract
Human immunodeficiency virus type 1 (HIV-1) is not eliminated from patients even after years of antiretroviral therapy, apparently due to the presence of latently infected cells. Here we describe the development of a cell-based system of latency that can be used for high-throughput screening aimed at novel drug discovery to eradicate HIV-1 infection.
摘要
即使经过多年的抗逆转录病毒治疗，1型人类免疫缺陷病毒（HIV-1）仍无法从患者体内清除，这显然是由于存在潜伏感染细胞。在此，我们描述了一种基于细胞的潜伏期系统的开发，该系统可用于高通量筛选，以发现根除HIV-1感染的新型药物。
相似文献
1
Human immunodeficiency virus type 1 latency model for high-throughput screening.用于高通量筛选的1型人类免疫缺陷病毒潜伏模型。
Antimicrob Agents Chemother. 2005 Dec;49(12):5185-8. doi: 10.1128/AAC.49.12.5185-5188.2005.
2
The challenge of viral reservoirs in HIV-1 infection.HIV-1感染中病毒储存库的挑战。
Annu Rev Med. 2002;53:557-93. doi: 10.1146/annurev.med.53.082901.104024.
3
Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy.接受有效抗逆转录病毒治疗的婴儿病毒库中人类免疫缺陷病毒1型的缓慢进化
AIDS Res Hum Retroviruses. 2007 Mar;23(3):381-90. doi: 10.1089/aid.2006.0175.
4
Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.给予组蛋白去乙酰化酶抑制剂以重新激活潜伏细胞储存库中的HIV-1表达：对治疗策略发展的启示
Biochem Pharmacol. 2004 Sep 15;68(6):1231-8. doi: 10.1016/j.bcp.2004.05.040.
5
[Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].[人类免疫缺陷病毒1型感染过程中的病毒动力学：发病机制特点及新的治疗前景]
Pathologica. 2000 Aug;92(4):291-3.
6
Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.接受高效抗逆转录病毒治疗（HAART）的HIV患者静息CD4 + T细胞库补充的限制因素
PLoS Pathog. 2007 Aug 31;3(8):e122. doi: 10.1371/journal.ppat.0030122.
7
Decelerating decay of latently infected cells during prolonged therapy for human immunodeficiency virus type 1 infection.在针对1型人类免疫缺陷病毒感染的长期治疗期间，潜伏感染细胞的衰减减速。
J Virol. 2002 Sep;76(17):8963-5. doi: 10.1128/jvi.76.17.8963-8965.2002.
8
Reservoirs for HIV infection and their persistence in the face of undetectable viral load.
AIDS Patient Care STDS. 2001 Oct;15(10):511-8. doi: 10.1089/108729101753205676.
9
Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs.事实与虚构：用于高通量筛选HIV-1激活药物的细胞模型
Curr HIV Res. 2011 Dec 1;9(8):568-78. doi: 10.2174/157016211798998826.
10
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.对接受联合抗逆转录病毒疗法的患者体内残留的HIV-1复制进行定量分析。
N Engl J Med. 1999 May 27;340(21):1605-13. doi: 10.1056/NEJM199905273402101.
引用本文的文献
1
Mechanism by Which PF-3758309, a Pan Isoform Inhibitor of p21-Activated Kinases, Blocks Reactivation of HIV-1 Latency.PF-3758309 是一种 p21 激活激酶的同工型抑制剂，通过何种机制阻断 HIV-1 潜伏期的再激活。
Biomolecules. 2023 Jan 4;13(1):100. doi: 10.3390/biom13010100.
2
Cure and Long-Term Remission Strategies.治愈与长期缓解策略
Methods Mol Biol. 2022;2407:391-428. doi: 10.1007/978-1-0716-1871-4_26.
3
Diversity of small molecule HIV-1 latency reversing agents identified in low- and high-throughput small molecule screens.在低通量和高通量小分子筛选中鉴定到的小分子 HIV-1 潜伏逆转剂的多样性。
Med Res Rev. 2020 May;40(3):881-908. doi: 10.1002/med.21638. Epub 2019 Oct 13.
4
Inhibitors of Signaling Pathways That Block Reversal of HIV-1 Latency.阻断 HIV-1 潜伏逆转的信号通路抑制剂。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01744-18. Print 2019 Feb.
5
Identification of benzazole compounds that induce HIV-1 transcription.鉴定可诱导HIV-1转录的苯并唑化合物。
PLoS One. 2017 Jun 28;12(6):e0179100. doi: 10.1371/journal.pone.0179100. eCollection 2017.
6
Identification of small molecule modulators of HIV-1 Tat and Rev protein accumulation.HIV-1反式激活转录蛋白（Tat）和调节蛋白（Rev）积累的小分子调节剂的鉴定
Retrovirology. 2017 Jan 26;14(1):7. doi: 10.1186/s12977-017-0330-0.
7
Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells.含有苯甲酰胺官能团和吡啶基封端的组蛋白去乙酰化酶抑制剂是原发性静息CD4+T细胞中优先有效的人类免疫缺陷病毒1型潜伏逆转剂。
J Gen Virol. 2017 Apr;98(4):799-809. doi: 10.1099/jgv.0.000716. Epub 2017 Apr 27.
8
Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication.一种新型化合物对SRSF10剪接调节功能的调节作用，该化合物可损害HIV-1复制。
Nucleic Acids Res. 2017 Apr 20;45(7):4051-4067. doi: 10.1093/nar/gkw1223.
9
Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication.蛋白酶体抑制剂作为人免疫缺陷病毒 1 潜伏和复制的双功能拮抗剂。
Retrovirology. 2013 Oct 24;10:120. doi: 10.1186/1742-4690-10-120.
10
Characterization of novel inhibitors of HIV-1 replication that function via alteration of viral RNA processing and rev function.新型 HIV-1 复制抑制剂的特性研究，这些抑制剂通过改变病毒 RNA 加工和 rev 功能发挥作用。
Nucleic Acids Res. 2013 Nov;41(20):9471-83. doi: 10.1093/nar/gkt727. Epub 2013 Aug 13.
本文引用的文献
1
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.体内潜伏性HIV-1感染的清除：一项概念验证研究。
Lancet. 2005;366(9485):549-55. doi: 10.1016/S0140-6736(05)67098-5.
2
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity.慢病毒正反馈回路中的随机基因表达：HIV-1 Tat 波动驱动表型多样性。
Cell. 2005 Jul 29;122(2):169-82. doi: 10.1016/j.cell.2005.06.006.
3
Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription.抑制人类免疫缺陷病毒转录的染色体特征的全基因组分析。
J Virol. 2005 Jun;79(11):6610-9. doi: 10.1128/JVI.79.11.6610-6619.2005.
4
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression.从静息CD4 T细胞中诱导出HIV-1：组蛋白去乙酰化酶抑制可使潜伏病毒表达。
AIDS. 2004 May 21;18(8):1101-8. doi: 10.1097/00002030-200405210-00003.
5
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.在体外对T细胞进行急性感染后，HIV可重复性地建立潜伏感染。
EMBO J. 2003 Apr 15;22(8):1868-77. doi: 10.1093/emboj/cdg188.
6
Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency.对潜伏状态下的1型人类免疫缺陷病毒激活进行直接和定量的单细胞分析。
J Virol. 2002 Sep;76(17):8776-86. doi: 10.1128/jvi.76.17.8776-8786.2002.
7
The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation.人类基因组中HIV-1整合位点决定基础转录活性及对Tat反式激活的反应。
EMBO J. 2001 Apr 2;20(7):1726-38. doi: 10.1093/emboj/20.7.1726.
8
An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.一种用于在无HIV-1辅助蛋白情况下安全、高效生产慢病毒载体的可诱导包装细胞系统。
Virology. 2001 Mar 30;282(1):77-86. doi: 10.1006/viro.2000.0787.
9
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.1型人类免疫缺陷病毒接种增强了病毒结合介导的感染。
J Virol. 2000 Nov;74(21):10074-80. doi: 10.1128/jvi.74.21.10074-10080.2000.
10
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.既往病毒储存库与高效抗逆转录病毒治疗中断后血浆病毒血症再次出现之间的关系。
Nat Med. 2000 Jul;6(7):757-61. doi: 10.1038/77481.
Zotero 插件